Progress and controversy of neoadjuvant therapy for locally advanced gastric cancer

Gastric cancer is one of the most common malignant tumors in the world. China is still the country with the highest incidence of gastric cancer and most patients with gastric cancer are in locally advanced stage at the first diagnosis. Traditional radical surgery combined with post-operative adjuvant treatment is difficult to further improve the prognosis of patients. In recent years, the exploration and application of neoadjuvant treatment modes such as chemotherapy, radio-therapy, targeted therapy and immunotherapy in locally advanced gastric cancer have made continuous progress. However, there is still no consensus on the benefit population, regimen options, and efficacy evaluation of neoadjuvant therapy. The authors review and comb the research progress and controversy of neoadjuvant therapy for locally advanced gastric cancer.